These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1905809)

  • 1. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.
    Williams RL; Thakker KM; John V; Lin ET; Liang-Gee W; Benet LZ
    Pharm Res; 1991 Jun; 8(6):744-9. PubMed ID: 1905809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose proportionality of transdermal nitroglycerin.
    Jewell RC; Banfield CR; Ruggirello DA; Huang YW; Noonan PK; Gonzalez MA
    Pharm Res; 1992 Oct; 9(10):1284-9. PubMed ID: 1448427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses.
    Nakashima E; Rigod JF; Lin ET; Benet LZ
    Clin Pharmacol Ther; 1990 May; 47(5):592-8. PubMed ID: 2111749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
    Nakashima E; Noonan PK; Benet LZ
    J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique.
    Sun JX; Piraino AJ; Morgan JM; Joshi JC; Cipriano A; Chan K; Redalieu E
    J Clin Pharmacol; 1995 Apr; 35(4):390-7. PubMed ID: 7650229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration.
    Noonan PK; Benet LZ
    Clin Pharmacol Ther; 1987 Sep; 42(3):273-7. PubMed ID: 3113806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch.
    Santoro A; Rovati LC; Setnikar I; Caplain H; Gualano V
    Arzneimittelforschung; 2000 Sep; 50(9):779-85. PubMed ID: 11050693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets.
    Kwon HR; Green P; Curry SH
    Biopharm Drug Dispos; 1992 Mar; 13(2):141-52. PubMed ID: 1550909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of organic nitrates in man: an overview.
    Bogaert MG
    Eur Heart J; 1988 Jan; 9 Suppl A():33-7. PubMed ID: 3137070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites.
    Jensen KM; Dahl JB
    Arzneimittelforschung; 1994 Aug; 44(8):951-3. PubMed ID: 7945539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis.
    Ogiso T; Iwaki M; Kanokogi A; Terao Y
    Chem Pharm Bull (Tokyo); 1990 Oct; 38(10):2829-33. PubMed ID: 2127557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch.
    Santoro A; Rovati LC; Follet M; Setnikar I; Caplain H; Gualano V
    Arzneimittelforschung; 2000 Sep; 50(9):786-94. PubMed ID: 11050694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers.
    Hutt V; Sauter K; Pabst G; Bonn R; Fritschi E
    Arzneimittelforschung; 1994 Dec; 44(12):1317-21. PubMed ID: 7848350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of a new transdermal nitroglycerin delivery system.
    Noonan PK; Gonzalez MA; Ruggirello D; Tomlinson J; Babcock-Atkinson E; Ray M; Golub A; Cohen A
    J Pharm Sci; 1986 Jul; 75(7):688-91. PubMed ID: 3093667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human maternal and fetal plasma glyceryl trinitrate concentrations.
    Bustard MA; Ryan G; Seaward G; Saleniak ME; Smith GN
    Am J Obstet Gynecol; 2003 Dec; 189(6):1777-8. PubMed ID: 14710114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography.
    Isenschmid M; Müller M; Bührer M; Vorkauf H; Bircher J
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):345-51. PubMed ID: 3928505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioavailability of oral nitroglycerin.
    Noonan PK; Benet LZ
    J Pharm Sci; 1986 Mar; 75(3):241-3. PubMed ID: 3084757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).
    Imhof PR; Vuillemin T; Gérardin A; Racine A; Müller P; Follath F
    Eur J Clin Pharmacol; 1984; 27(1):7-12. PubMed ID: 6436032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin.
    Parker JD
    J Cardiovasc Pharmacol; 1996 Nov; 28(5):631-8. PubMed ID: 8945675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.
    Abrams J
    Drugs; 1987 Sep; 34(3):391-403. PubMed ID: 3119308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.